



under the aegis of
Mumbai Hematology Group



Wednesday, 3rd June 2026

Subject 1: 06.30 pm (IST) onwards

Rational use of polatuzumab in newly diagnosed DLBCL - A case based discussion



Dr. M. B. Agarwal, MD

Prof & Head
Dept of Hematology
Bombay Hospital Institute of
Medical Sciences
Mumbai

Subject 2: 07.30 pm (IST) Mountain time : 8.00 am

Clinically pertinent advances in therapies of B-cell lymphomas




Dr. Manali Kamdar

Associate Professor of Medicine
The University of Colorado
School of Medicine
Clinical Director of the lymphoma program
Aurora, Colorado, USA

Supported by:



www.mhgindia.com



Dr. M. B. Agarwal, MD

Prof & Head
Dept of Hematology
Bombay Hospital Institute of
Medical Sciences
Mumbai

Bio-sketch

- Prof & Head, Dept of Hematology, Bombay Hospital Institute of Medical Sciences, Mumbai.
- Hon. hematologist: P D Hinduja Hospital, Lilavati Hospital, Breach Candy Hospital, Mumbai.
- Ex-Hon. Prof, Div of hematology, Dept of Medicine, Lokmanya Tilak Municipal Medical College (LTMMC), Sion, Mumbai
- Fellow: College of Hematologists of Sri Lanka (2016-26).
- Counsellor: SOHO (Society of Hematologic Oncology, MD Anderson Cancer Centre, Houston, Texas, USA) - representing India.
- President : Mumbai Haematology Group (2025-26).
- Past president: Indian Society of Haematology (2010-11).
- Advisor: Thalassemia International Federation
- Advisor: Thalassemia Society, Maldives.
- Lifetime Achievement award by Indian Society of Hematology & Blood Transfusion (2025)
- He has received 25 Orations & various Awards from national and international bodies.
- His major contribution in the field of hematology is in the field of education.
- He has published a yearbook in hematology called "Haematology Today" which used to be a multi-author venture containing 60-70 chapters based on recent advances in the field. This book was published every year from 2005 until 2018.
- He has keen interest in clinical research. His original contributions are in the field of multiple myeloma, chronic myeloid leukaemia (CML), iron chelation, antiphospholipid syndrome (APS) & acquired coagulopathies.
- During last 40 years, he has published over 120 original articles in various international and national journals.



Dr. Manali Kamdar

Associate Professor of Medicine
The University of Colorado
School of Medicine
Clinical Director of the lymphoma program
Aurora, Colorado, USA

She obtained her medical degree from Mumbai, India, and subsequently completed a residency in Internal Medicine and a fellowship in Hematology and Oncology at the East Carolina University in Greenville, North Carolina.

She then completed another fellowship in lymphoid malignancies and bone marrow transplantation at Stanford University.

Subspecializing in lymphomas appealed to her because of the clinical heterogeneity with each subtype, scientifically stimulating biology, opportunity to tailor therapeutics, and the endless possibilities of new drug development.

Currently, she is an Associate Professor of Medicine at the University of Colorado School of Medicine and serve as the Clinical Director of the lymphoma program. Her clinical and research interests include B cell lymphomas, particularly refractory diffuse large B-cell lymphoma, mantle cell lymphomas, and other indolent lymphomas.

In addition to seeing patients with lymphoma in clinic, her research involves conducting clinical trials of novel drugs, including immunotherapy and combinations in these diseases.

She has had the opportunity to serve in organizations at the national level. This included working with the National Comprehensive Cancer Network guidelines committee and Southwest Oncology Group lymphoma committee, where she served as a cadre member of the chronic lymphocytic leukemia and lymphoma working groups, respectively.

Her goal is to develop nuanced approaches of personalized medicine in lymphoid malignancies, and she is currently collaborating with several clinical as well as laboratory-based investigators in the United States.

Her eventual hope is to make these fascinating discoveries efficacious, durable, and affordable so that they have a far-reaching impact on patients everywhere.

Scientific Agenda



Welcome note and introduction of guest speaker
Dr. M. B. Agarwal, Mumbai

Guest lecture

Subject 1: Rational use of polatuzumab in newly diagnosed DLBCL – A case based discussion

Speaker: Dr. M. B. Agarwal, Mumbai

Subject 2: Clinically pertinent advances in therapies of B-cell lymphomas

Speaker: Dr. Manali Kamdar, Aurora, USA

Interactive session with Indian discussants

Moderator Dr. M. B. Agarwal, Mumbai

Vote of thanks Dr. M. B. Agarwal, Mumbai

Registration Link



Click on below link to register:

<https://forms.gle/zoZr5d2kuo7v1W9t6>

All registered delegates will receive the attendee joining link on your registered email id. You may also visit our website www.mhgindia.com

Please send your queries related to the webinar on kalpesh@perfectsquare.co.in.



under the aegis of
Mumbai Hematology Group

Hematology Centre, Ghamat Lodge,
804-A, Dr. B. Ambedkar Road,
Dadar TT, Mumbai 400014.
Email ID: mbagarwal1@gmail.com

Supported by:



Event Partner:

